scholarly journals 8-Year Survival with a Metastatic Thymic Neuroendocrine Tumor: Emphasis on Redefining “Treatment Objectives” Using “Personalized” Peptide Receptor Radionuclide Therapy with177LU- and90Y-Labeled Somatostatin Analogs

2015 ◽  
Vol 1 (2) ◽  
pp. e131-e135 ◽  
Author(s):  
Ameya D. Puranik ◽  
Harshad R. Kulkarni ◽  
Aviral Singh ◽  
Richard P. Baum
Keyword(s):  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Somatostatin Analogs ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals A Case of Primary Hepatic Neuroendocrine Tumor and Literature Review

2021 ◽  
pp. 90-97
Author(s):  
Pak Chiu Wong ◽  
Wong Hoi She ◽  
Ui Soon Khoo ◽  
Tan To Cheung
Keyword(s):  
Liver Resection ◽  
Neuroendocrine Tumor ◽  
Preoperative Diagnosis ◽  
Radionuclide Therapy ◽  
Tumor Recurrence ◽  
Peptide Receptor Radionuclide Therapy ◽  
Rare Tumor ◽  
Major Liver Resection ◽  
Peptide Receptor ◽  
Primary Hepatic Neuroendocrine Tumor

We report an unusual presentation of primary hepatic neuroendocrine tumor which was initially misdiagnosed as intrahepatic cholangiocarcinoma. The diagnosis was only revealed after a major liver resection by histopathology. With adjuvant lanreotide injection, the patient survived for more than 16 months after the operation without tumor recurrence. Diagnosis of this rare tumor has been a major challenge and we emphasize the importance of a preoperative diagnosis. Surgical resection remains the mainstay for curative treatment, while peptide receptor radionuclide therapy is an emerging treatment option which has provided promising results.

scholarly journals Somatostatin receptor radionuclide therapy in neuroendocrine tumors

2021 ◽  
Vol 28 (3) ◽  
pp. R81-R93
Author(s):  
Mintallah Haider ◽  
Satya Das ◽  
Taymeyah Al-Toubah ◽  
Eleonora Pelle ◽  
Ghassan El-Haddad ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Somatostatin Analogs ◽  
Peptide Receptor Radionuclide Therapy ◽  
Study Data ◽  
Combination Therapies ◽  
Peptide Receptor ◽  
Therapeutic Landscape ◽  
Receptor Agonists And Antagonists

Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review summarizes study data supporting the use of radiolabeled somatostatin analogs for the treatment of advanced NETs and highlights risks, including potential toxicities in specific populations. Key ongoing clinical trials, including randomized studies, are designed to better define the position of PRRT within the broader therapeutic landscape. Preclinical and early-phase human studies are focused on the development of novel somatostatin-receptor agonists and antagonists, new radionuclides, and radiosensitizing combination therapies.

scholarly journals Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor

Oncotarget ◽  
2018 ◽  
Vol 9 (37) ◽  
pp. 24693-24706 ◽  
Author(s):  
Nupur K. Purohit ◽  
Rashmi G. Shah ◽  
Samuel Adant ◽  
Michael Hoepfner ◽  
Girish M. Shah ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Cells ◽  
Radionuclide Therapy ◽  
Parp Inhibitor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

Sa1152 TUMOR RESPONSE TO PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN A UNITED STATES-BASED NEUROENDOCRINE TUMOR COHORT

2020 ◽  
Vol 158 (6) ◽  
pp. S-292
Author(s):  
Sarit T. Kipnis ◽  
Matthew Hung ◽  
Jason Heckert ◽  
Bonita J. Bennett ◽  
Caroline Creamer ◽  
...  
Keyword(s):  
United States ◽  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Tumor Response ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor
Sign in / Sign up

Export Citation Format

Share Document